Abstract
Recombinant human granulocyte colony-stimulating factors (G-CSFs) are used for mobilisation of peripheral blood stem cells (PBSCs) and their subsequent infusion. Lenograstim is the glycosylated recombinant form of human G-CSF. Compared with filgrastim, lenograstim has a greater capacity to stimulate the colony growthin vitroof both purified CD34 and unmanipulated PBSCs. Due to the increased potency of lenograstim, several clinical studies were carried out to show the comparative efficacy of reduced or standard doses of lenograstim for PBSC mobilisation and transplantation.In vivoprospective randomised studies indicate that lenograstim is more potent than filgrastim. Shortcourse low-dose lenograstim was found to be as effective as the standard dose in reducing neutrophil engraftment time following high-dose chemotherapy and PBSC recovery. Lenograstim at a 25% lower dose does not negatively affect the number of CD34+ stem cells harvested or the engraftment results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
